Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05856084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 28, 2024 to Sep 1, 2025 Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Mar 31, 2026 to Apr 10, 2026
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 5 of 13 entries
  2. Primary completion date: Feb 28, 2024 to Dec 28, 2024v3
  3. Primary completion date: Sep 2025 to Feb 28, 2024v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study completion date: Sep 2025 to Mar 31, 2026
    • Start date changed from estimate of May 2023 to May 7, 2023
    • Site contact updated
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
Trial Details
NCT Number NCT05856084
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions
(from sponsor)		 Herpes Zoster
Related terms Herpes Zoster
Enrollment 924 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov